{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:10:07Z","timestamp":1790352607787,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["4004-00485B"],"award-info":[{"award-number":["4004-00485B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["6239"],"award-info":[{"award-number":["6239"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bcp.2023.115793","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T17:08:29Z","timestamp":1694106509000},"page":"115793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Functional assay for assessment of agonistic or antagonistic activity of angiotensin AT2 receptor ligands reveals that EMA401 and PD123319 have agonistic properties"],"prefix":"10.1016","volume":"216","author":[{"given":"A. Augusto","family":"Peluso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor M.","family":"Souza-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Villela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille B.L.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hallberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Sumners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. Muscha","family":"Steckelings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115793_b0005","doi-asserted-by":"crossref","unstructured":"U.M. Steckelings, T. Unger, The Renin\u2014Angiotensin\u2014Aldosterone System, in: Man. Hypertens. Eur. Soc. Hypertens. Third Ed., 3rd ed., CRC Press, 2019.","DOI":"10.1201\/9780429199189-15"},{"key":"10.1016\/j.bcp.2023.115793_b0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2023.115793_b0015","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/pharmrev.120.000281","article-title":"The angiotensin AT2 receptor: from a binding site to a novel therapeutic target","volume":"74","author":"Steckelings","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2023.115793_b0020","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(13)62337-5","article-title":"EMA401-003 study group, EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"383","author":"Rice","year":"2014","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.bcp.2023.115793_b0025","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1097\/j.pain.0000000000002252","article-title":"Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy","volume":"162","author":"Rice","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2023.115793_b0030","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1021\/jm049715t","article-title":"Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist","volume":"47","author":"Wan","year":"2004","journal-title":"J. Med. Chem."},{"issue":"55","key":"10.1016\/j.bcp.2023.115793_b0035","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.109.147843","article-title":"Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB","volume":"1979","author":"Rompe","year":"2010","journal-title":"Hypertens. Dallas Tex"},{"issue":"129","key":"10.1016\/j.bcp.2023.115793_b0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/CS20150077","article-title":"\u03b2-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats","volume":"1979","author":"Del Borgo","year":"2015","journal-title":"Clin. Sci. Lond. Engl."},{"key":"10.1016\/j.bcp.2023.115793_b0045","first-page":"1557","article-title":"A small molecule angiotensin II type 2 receptor (AT\u2082R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44\/p42 MAPK activation in the dorsal root ganglia","volume":"14","author":"Smith","year":"2013","journal-title":"Pain Med. Malden Mass."},{"issue":"46","key":"10.1016\/j.bcp.2023.115793_b0050","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1161\/01.HYP.0000193504.51489.cf","article-title":"The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy","volume":"1979","author":"D\u2019Amore","year":"2005","journal-title":"Hypertens. Dallas Tex"},{"issue":"132","key":"10.1016\/j.bcp.2023.115793_b0055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1042\/CS20171598","article-title":"Identification of protein phosphatase involvement in the AT2 receptor-induced activation of endothelial nitric oxide synthase","volume":"1979","author":"Peluso","year":"2018","journal-title":"Clin. Sci. Lond. Engl."},{"issue":"7","key":"10.1016\/j.bcp.2023.115793_b0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1042\/CS20171598","article-title":"Identification of protein phosphatase involvement in the AT2-receptor induced activation of endothelial nitric oxide synthase","volume":"132","author":"Peluso","year":"2018","journal-title":"Clin. Sci. Lond. Engl."},{"key":"10.1016\/j.bcp.2023.115793_b0065","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bjp.0703566","article-title":"Differential role of angiotensin II receptor subtypes on endothelial superoxide formation","volume":"131","author":"Sohn","year":"2000","journal-title":"Br. J. Pharmacol."},{"issue":"45","key":"10.1016\/j.bcp.2023.115793_b0070","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.HYP.0000160325.59323.b8","article-title":"Angiotensin-(1\u20137) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats","volume":"1979","author":"Walters","year":"2005","journal-title":"Hypertens. Dallas Tex"},{"key":"10.1016\/j.bcp.2023.115793_b0075","unstructured":"T. Wang, Z. Li, M.E. Cvijic, C. Krause, L. Zhang, C.S. Sum, Measurement of \u03b2-Arrestin Recruitment for GPCR Targets, in: G.S. Sittampalam, N.P. Coussens, K. Brimacombe, A. Grossman, M. Arkin, D. Auld, C. Austin, J. Baell, B. Bejcek, T.D.Y. Chung, J.L. Dahlin, V. Devanaryan, T.L. Foley, M. Glicksman, M.D. Hall, J.V. Hass, J. Inglese, P.W. Iversen, S.D. Kahl, S.C. Kales, M. Lal-Nag, Z. Li, J. McGee, O. McManus, T. Riss, O.J. Trask, J.R. Weidner, M. Xia, X. Xu (Eds.), Assay Guid. Man., Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD), 2004. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK464634\/ (accessed March 18, 2018)."},{"key":"10.1016\/j.bcp.2023.115793_b0080","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.cellsig.2011.06.011","article-title":"Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles","volume":"23","author":"Porrello","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcp.2023.115793_b0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature22035","article-title":"Structural basis for selectivity and diversity in angiotensin II receptors","volume":"544","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115793_b0090","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1210\/endo-128-4-1947","article-title":"Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor","volume":"128","author":"Pucell","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2023.115793_b0095","first-page":"C1389","article-title":"Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein","volume":"267","author":"Kang","year":"1994","journal-title":"Am. J. Phys. Anthropol."},{"issue":"33","key":"10.1016\/j.bcp.2023.115793_b0100","doi-asserted-by":"crossref","first-page":"24539","DOI":"10.1016\/S0021-9258(19)74498-6","article-title":"Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors","volume":"268","author":"Mukoyama","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115793_b0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0922-4106(91)90091-U","article-title":"Angiotensin II AT2 receptors do not interact with guanine nucleotide binding proteins","volume":"207","author":"Bottari","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115793_b0110","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","article-title":"The AT2 receptor\u2013a matter of love and hate","volume":"26","author":"Steckelings","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2023.115793_b0115","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1016\/j.bmc.2008.05.066","article-title":"Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships","volume":"16","author":"Wallinder","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"57","key":"10.1016\/j.bcp.2023.115793_b0120","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/HYPERTENSIONAHA.110.164301","article-title":"A single beta-amino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular function","volume":"1979","author":"Jones","year":"2011","journal-title":"Hypertens. Dallas Tex"},{"issue":"1","key":"10.1016\/j.bcp.2023.115793_b0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0303-7207(95)03586-V","article-title":"Characterization of a rat type 2 angiotensin II receptor stably expressed in 293 cells","volume":"112","author":"Mukoyama","year":"1995","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2023.115793_b0130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2017.08.039","article-title":"Candesartan prevents resiniferatoxin-induced sensory small-fiber neuropathy in mice by promoting angiotensin II-mediated AT2 receptor stimulation","volume":"126","author":"Bessaguet","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2023.115793_b0135","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cell.2014.04.040","article-title":"Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways","volume":"157","author":"Marion","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115793_b0140","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1097\/j.pain.0000000000001361","article-title":"Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia","volume":"159","author":"Bessaguet","year":"2018","journal-title":"Pain"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:54:36Z","timestamp":1757771676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223003842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":28,"alternative-id":["S0006295223003842"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115793","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional assay for assessment of agonistic or antagonistic activity of angiotensin AT2 receptor ligands reveals that EMA401 and PD123319 have agonistic properties","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115793"}}